Senior Director, Oncology, Precision Medicine (pre-IND, IND, Ph1-3, and life cycle management) @ AbbVie
Head of Translational Medicine at Pharmacyclics(an AbbVie Company)with added leadership at RWC site @ AbbVie
Group Director, Head of Early Asset Immuno-Oncology Clinical Biomarkers (IND, Ph1, and Ph2) @ Bristol Myers Squibb
Associate Director,Biomarker Subteam Leader,Head of GI Biomarker Strategy Team(IND, Ph1, Ph2, Ph3) @ Genentech
Principal Research Investigator, Late Stage Drug Discovery Program Leader (Lead opt to GLP-Tox) @ Sanofi
Investigator I-III, Project Team Leader (Target ID and Val, hit finding, hit-to-lead, lead nomination) @ Novartis
Post-doctoral Scientist at Genomics Institute of the Novartis Research Foundation (GNF) @ Novartis
Alex Huang's Education
University of Rochester School of Medicine and Dentistry
PhD
1997 - 2002
National Taiwan University
BS
1990 - 1994
Alex Huang's Skills
Oncology
Drug Discovery
Translational Research
Signal Transduction
Biomarker Discovery
Translational Medicine
Genetics
Assay Development
Biomarkers
Cancer Research
Alex Huang's Summary
Alex Huang, based in United States, is currently a Vice President, Head of Cell Therapy at BeiGene, bringing experience from previous roles at AbbVie, Bristol-Myers Squibb and Genentech. Alex Huang holds a 1997 - 2002 PhD @ University of Rochester School of Medicine and Dentistry. With a robust skill set that includes Oncology, Drug Discovery, Translational Research, Signal Transduction, Biomarker Discovery and more, Alex Huang contributes valuable insights to the industry. Alex Huang has 2 emails on RocketReach.